CalciMedica, Inc.

CALC Nasdaq CIK: 0001534133

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, 92037
Mailing Address 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, 92037
Phone 858-952-5500
Fiscal Year End 1231
EIN 452120079

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 18, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
10-K Annual financial report March 3, 2026 View on SEC
S-3 Shelf registration for future offerings March 3, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 6, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) December 1, 2025 View on SEC
8-K Current report of material events November 12, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC

Annual Reports

10-K March 3, 2026
  • Completed patient enrollment for lead candidate Auxora in acute pancreatitis, with top-line data expected in early 2026.
  • Successfully raised capital through a public stock offering, strengthening the balance sheet and extending operational runway.
View Analysis

Material Events

8-K Financial Distress March 18, 2026
High Impact
  • CalciMedica reported positive Phase 2b clinical trial results for its lead drug candidate, Auxora, in acute pancreatitis.
  • The company has specific deadlines (September 2024) to regain Nasdaq compliance for both market capitalization and bid price.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.